A new NITI Aayog report reveals that India sources 65% of its Active Pharmaceutical Ingredients (APIs) from China. This high dependence exposes the industry to supply chain risks and cost fluctuations. Investors should watch how companies manage these pressures and adapt through local manufacturing.
What Happened
NITI Aayog, the government’s public policy think tank, released its latest "Trade Watch Quarterly" report, which highlights a major challenge for the Indian pharmaceutical industry: a heavy reliance on China. The data shows that approximately 65% of the Active Pharmaceutical Ingredients (APIs), key starting materials, and drug intermediates required by Indian manufacturers are imported from China.
APIs are the essential building blocks that give medicines their therapeutic effect. While India is often called the "pharmacy of the world" because of its massive production of affordable generic medicines, this heavy import dependence creates a structural risk. The report notes that this vulnerability is particularly high in fermentation-based products, which are complex to manufacture.
The Cost And Supply Risk
For investors, this dependency is not just a trade statistic; it directly impacts company profitability. When India relies so heavily on a single country for raw materials, any disruption in supply chains or price increases in China can hit the bottom line of Indian drugmakers.
Rising environmental compliance costs, both in India and abroad, have further complicated the manufacturing landscape. These costs, combined with the difficulty of setting up complex fermentation-based API units, have historically made it cheaper and easier for Indian firms to import from China rather than producing locally. However, this keeps Indian firms exposed to global supply shocks, which can squeeze profit margins when raw material prices rise unexpectedly.
Moving Up The Value Chain
The report emphasizes that India must move beyond being a high-volume supplier of generics. NITI Aayog officials, including Vice Chairman Ashok Kumar Lahiri, noted that while India’s volume is high, the country needs to focus on "value." This means shifting toward producing higher-margin, branded products rather than just low-cost generics.
To achieve this, the government is promoting collaboration between industry players and academic institutions to boost research and development. The goal is to build a domestic ecosystem that can support local manufacturing, thereby reducing the reliance on imports for critical drug components.
Ongoing Efforts To Reduce Dependence
It is important to note that this is not the first time India has addressed this reliance. The government has already implemented the Production Linked Incentive (PLI) scheme, which offers financial incentives to companies that manufacture key drug ingredients within India.
Investors are already familiar with this push, as several major Indian pharmaceutical companies have begun investing in local API manufacturing facilities under these government schemes. However, the NITI Aayog report serves as a reminder that the transition to self-sufficiency is a long-term process rather than an overnight fix.
What Investors Should Track
Investors looking at the pharmaceutical sector may want to monitor a few key areas:
- Gross Margin Trends: Check if companies are successfully passing on raw material cost increases or if their margins are tightening due to import costs.
- PLI Progress: Track whether companies you are interested in are successfully commissioning and using their new local manufacturing capacity under the government’s incentive schemes.
- Supply Chain Diversity: Look for management commentary on efforts to source raw materials from countries other than China or to produce them in-house.
- Innovation Spending: Higher spending on R&D for complex, high-value products could indicate a shift toward the strategy suggested by NITI Aayog, though this usually comes with higher near-term costs.